ArticleJournal of clinical medicine research2026
Efficacy and Safety of Regional Citrate Anticoagulation in Neurocritical Care Patients With Chronic Severe Hypernatremia Undergoing Continuous Renal Replacement Therapy: A Single-Center Retrospective Study.
Article in Journal of clinical medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypernatremia is a common complication among neurocritical care patients. This study aimed to investigate the effectiveness and safety of regional citrate anticoagulation (RCA) vs. no anticoagulation (NA) in neurocritical patients receiving continuous renal replacement therapy (CRRT) who also had chronic severe hypernatremia and an elevated risk of bleeding. Methods: From March 2020 to August 2024, electronic medical records of neuro-critically ill patients who underwent CRRT for chronic severe hypernatremia with elevated risk of bleeding at Henan Provincial People's Hospital's neurocritical intensive care unit (ICU) were retrospectively analyzed. Patients were divided into RCA (n = 70) and NA (n = 28) groups. The key effectiveness objective was the mean serum sodium correction, while the primary safety event was the occurrence of common anticoagulant adverse events. Original cohorts were matched using propensity score matching (PSM) between two groups (n = 21). Risk factors impacting the initial filter lifespan were analyzed using Cox proportional risk regression model. Results: Both groups achieved similar sodium correction rates (0.5 ± 0.1 mmol/L/h). The RCA group had a lower incidence of both hemorrhagic (6/70 (8.6%) and 8/28 (28.6%), P = 0.021) and filter coagulation (0/70 (0%) and 17/28 (60.7%), P < 0.001) adverse events. After performing Kaplan-Meier curve and multivariable Cox regression, RCA was identified as an independent protective factor for first filter lifespan (hazard ratio (HR) = 0.09, 95% confidence interval (CI), 0.05-0.18). Conclusion: RCA is safer and equally effective as NA for CRRT in neurocritical patients with chronic severe hypernatremia, reducing bleeding and filter clotting risks. While our retrospective study suggests that RCA is a safe and effective strategy in this population, the findings require validation in a large-scale, randomized controlled trial to establish conclusive evidence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.